BA
The Boeing Company
BA offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
NDSN
Nordson Corporation
NDSN has the edge over BA overall, supported by lower modeled downside and stronger fundamentals.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
NDSN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
NDSN's revenue, profitability, cash flow and balance sheet are all currently healthy.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA has the edge over NDSN in the historical PE scenario, which offers more potential upside but is not a forecast.
NDSN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $327 | — |
| Cheap | 26x | $258 | -21% |
| Fair | 29x | $289 | -11% |
| Current | 33x | $327 | — |
| Expensive | 35x | $343 | +4.9% |
Historical ranges are pointers, not guarantees.
NDSN's PE is in its expensive range at 33x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its cheap range.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
NDSN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for NDSN, with profitability improving.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has returned to profit: it earned $9.66 per share over the past year, after losing money the year before.
NDSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.90 | +31% |
| Q3 2026 | $9.87 | +24% |
| Q2 2026 | $9.36 | +20% |
| Q1 2026 | $9.24 | +18% |
| Q4 2025 | $8.51 | +4.9% |
| Q3 2025 | $7.96 | -3% |
| Q2 2025 | $7.78 | -7.3% |
| Q1 2025 | $7.86 | -8.1% |
| Q4 2024 | $8.11 | -4.1% |
NDSN earned $9.87 per share over the past year, up 24% from the year before.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over NDSN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA's operating margin was 1.5% last quarter, up 22 points from the same quarter a year ago.
NDSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $817.7M | +10% |
| Q2 2026 | $740.8M | +8.5% |
| Q1 2026 | $669.5M | +8.8% |
| Q4 2025 | $751.8M | +1% |
| Q3 2025 | $741.5M | +12% |
| Q2 2025 | $682.9M | +5% |
| Q1 2025 | $615.4M | -2.8% |
| Q4 2024 | $744.5M | +3.5% |
NDSN's revenue has grown year over year for six quarters in a row: $818M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +2 points |
| Q2 2026 | 27% | +1.9 points |
| Q1 2026 | 25% | +2 points |
| Q4 2025 | 29% | +4.5 points |
| Q3 2025 | 25% | +0.1 points |
| Q2 2025 | 25% | -1.2 points |
| Q1 2025 | 23% | -2.3 points |
| Q4 2024 | 24% | -1.7 points |
NDSN has the edge over BA on profitability, with a higher operating margin.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over NDSN on cash flow, with more consistent year-over-year improvement.
NDSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $236.8M | +4.6% |
| Q2 2026 | $170.5M | +65% |
| Q1 2026 | $122.9M | -11% |
| Q4 2025 | $193.9M | +156% |
| Q3 2025 | $226.4M | +58% |
| Q2 2025 | $103.1M | -4.7% |
| Q1 2025 | $137.7M | -16% |
| Q4 2024 | $75.8M | -50% |
NDSN's free cash flow has been positive every quarter for seven years: $724M over the past year, up 33% from the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has 793M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
NDSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -73K shares |
| 1 year | -1.2% | -701K shares |
| 3 years | -2.6% | -1.5M shares |
| 5 years | -4.6% | -2.7M shares |
| Available history | -3.7% | -2.2M shares |
NDSN has the edge over BA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $29.5M |
| Q2 2026 | $43.3M |
| Q1 2026 | $86M |
| Q4 2025 | $88.2M |
| Q3 2025 | $71.9M |
| Q2 2025 | $86.2M |
| Q1 2025 | $60.1M |
| Q4 2024 | $766,000 |
NDSN spent $247M buying back its own shares over the past year, up 13% from the year before.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
NDSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.8x | Healthy |
| Q2 2026 | 2.1x | Moderate |
| Q1 2026 | 2.3x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.6x | Moderate |
NDSN has the edge over BA on leverage, with a lower net debt burden relative to earnings.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
NDSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 52.5 | Neutral |
NDSN's weekly RSI is 60 (neutral) and its Stochastic is 52 (neutral).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA has the edge over NDSN on valuation relative to its sector.
NDSN PE vs Industrials Sector
| Metric | NDSN | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 24x | 37% above |
| PE % | 79 | 58 | 21 pts above |
NDSN is trading at 33x earnings, a 37% premium to the Industrials sector's median of 24x.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
NDSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $323.5 | 1% above |
| 20 week MA | $313.4 | 4.2% above |
| 50 week MA | $289.4 | 13% above |
| 100 week MA | $251.8 | 30% above |
| 200 week MA | $246.9 | 32% above |
NDSN has the edge over BA on trend strength, trading above more of its moving averages.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has finished lower in four of the last six years. It's down 21% so far in 2026.
NDSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.8 | $199.0 | +22% |
| 2021 | $199.0 | $253.7 | +27% |
| 2022 | $253.7 | $236.3 | -6.8% |
| 2023 | $236.3 | $264.2 | +12% |
| 2024 | $264.2 | $211.3 | -20% |
| 2025 | $211.3 | $244.0 | +15% |
| 2026 YTD | $244.0 | $326.6 | +34% |
NDSN has the edge over BA on returns for 2026, with the stronger performance.